Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Frontal Theta Asymmetry as a Biomarker of Depression.

Dharmadhikari AS, Tandle AL, Jaiswal SV, Sawant VA, Vahia VN, Jog N.

East Asian Arch Psychiatry. 2018 Mar;28(1):17-22.

2.

LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation.

Ho WS, Sizdahkhani S, Hao S, Song H, Seldomridge A, Tandle A, Maric D, Kramp T, Lu R, Heiss JD, Camphausen K, Gilbert MR, Zhuang Z, Park DM.

Cancer Lett. 2018 Feb 28;415:217-226. doi: 10.1016/j.canlet.2017.11.035. Epub 2017 Dec 2.

PMID:
29199006
3.

Computational analysis of the mesenchymal signature landscape in gliomas.

Celiku O, Tandle A, Chung JY, Hewitt SM, Camphausen K, Shankavaram U.

BMC Med Genomics. 2017 Mar 9;10(1):13. doi: 10.1186/s12920-017-0252-7.

4.

Multivariate Analysis of Radiation Responsive Proteins to Predict Radiation Exposure in Total-Body Irradiation and Partial-Body Irradiation Models.

Sproull M, Kramp T, Tandle A, Shankavaram U, Camphausen K.

Radiat Res. 2017 Feb;187(2):251-258. doi: 10.1667/RR14558.1. Epub 2017 Jan 24.

5.

Mitotic Protein Kinase 1: Role in Spindle Assembly Checkpoint Revisited.

Tandle A, Camphausen K.

J Cancer Clin Trials. 2016 May;1(2). pii: 111. Epub 2016 May 2. No abstract available.

6.

FOXM1 and STAT3 interaction confers radioresistance in glioblastoma cells.

Maachani UB, Shankavaram U, Kramp T, Tofilon PJ, Camphausen K, Tandle AT.

Oncotarget. 2016 Nov 22;7(47):77365-77377. doi: 10.18632/oncotarget.12670.

7.

Molecular profiling of MPS1 gene silencing in U251 glioma cell line.

Shankavaram U, Maachani UB, Zhao S, Camphausen K, Tandle A.

Genom Data. 2015 Dec 1;6:36-39.

8.

Serum Amyloid A as a Biomarker for Radiation Exposure.

Sproull M, Kramp T, Tandle A, Shankavaram U, Camphausen K.

Radiat Res. 2015 Jul;184(1):14-23. Epub 2015 Jun 26.

9.

Modulation of miR-21 signaling by MPS1 in human glioblastoma.

Maachani UB, Tandle A, Shankavaram U, Kramp T, Camphausen K.

Oncotarget. 2016 Aug 16;7(33):52912-52927. doi: 10.18632/oncotarget.4143.

10.

Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma.

Gordon IK, Lu J, Graves CA, Huntoon K, Frerich JM, Hanson RH, Wang X, Hong CS, Ho W, Feldman MJ, Ikejiri B, Bisht K, Chen XS, Tandle A, Yang C, Arscott WT, Ye D, Heiss JD, Lonser RR, Camphausen K, Zhuang Z.

Mol Cancer Ther. 2015 Jul;14(7):1540-1547. doi: 10.1158/1535-7163.MCT-14-0614. Epub 2015 May 4.

11.

Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.

Maachani UB, Kramp T, Hanson R, Zhao S, Celiku O, Shankavaram U, Colombo R, Caplen NJ, Camphausen K, Tandle A.

Mol Cancer Res. 2015 May;13(5):852-62. doi: 10.1158/1541-7786.MCR-14-0462-T. Epub 2015 Feb 26.

12.

Cell transcriptional state alters genomic patterns of DNA double-strand break repair in human astrocytes.

Yong RL, Yang C, Lu J, Wang H, Schlaff CD, Tandle A, Graves CA, Elkahloun AG, Chen X, Zhuang Z, Lonser RR.

Nat Commun. 2014 Dec 17;5:5799. doi: 10.1038/ncomms6799.

13.

Ionizing radiation and glioblastoma exosomes: implications in tumor biology and cell migration.

Arscott WT, Tandle AT, Zhao S, Shabason JE, Gordon IK, Schlaff CD, Zhang G, Tofilon PJ, Camphausen KA.

Transl Oncol. 2013 Dec 1;6(6):638-48. eCollection 2013 Dec 1.

14.

Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.

Tandle AT, Kramp T, Kil WJ, Halthore A, Gehlhaus K, Shankavaram U, Tofilon PJ, Caplen NJ, Camphausen K.

Eur J Cancer. 2013 Sep;49(14):3020-8. doi: 10.1016/j.ejca.2013.05.013. Epub 2013 Jun 18.

15.

Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102.

Buchanan IM, Scott T, Tandle AT, Burgan WE, Burgess TL, Tofilon PJ, Camphausen K.

J Cell Mol Med. 2011 Sep;15(9):1999-2006. doi: 10.1111/j.1582-4934.2010.01122.x. Epub 2010 Jul 12.

16.

Endothelial monocyte activating polypeptide-II modulates endothelial cell responses by degrading hypoxia-inducible factor-1alpha through interaction with PSMA7, a component of the proteasome.

Tandle AT, Calvani M, Uranchimeg B, Zahavi D, Melillo G, Libutti SK.

Exp Cell Res. 2009 Jul 1;315(11):1850-9. doi: 10.1016/j.yexcr.2009.03.021. Epub 2009 Apr 10.

PMID:
19362550
17.

Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature.

Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A, Newman S, Vail D, Henry C, Thamm D, Sorenmo K, Hajitou A, Pasqualini R, Arap W, Khanna C, Libutti SK.

PLoS One. 2009;4(3):e4972. doi: 10.1371/journal.pone.0004972. Epub 2009 Mar 30.

18.

Tumor vasculature-targeted delivery of tumor necrosis factor-alpha.

Tandle A, Hanna E, Lorang D, Hajitou A, Moya CA, Pasqualini R, Arap W, Adem A, Starker E, Hewitt S, Libutti SK.

Cancer. 2009 Jan 1;115(1):128-39. doi: 10.1002/cncr.24001.

19.

A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans.

Staquicini FI, Tandle A, Libutti SK, Sun J, Zigler M, Bar-Eli M, Aliperti F, PĂ©rez EC, Gershenwald JE, Mariano M, Pasqualini R, Arap W, Lopes JD.

Cancer Res. 2008 Oct 15;68(20):8419-28. doi: 10.1158/0008-5472.CAN-08-1242.

20.

Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.

Tandle A, Libutti SK.

Clin Adv Hematol Oncol. 2003 Jan;1(1):41-8. Review.

PMID:
16227959
21.

Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells.

Tandle AT, Mazzanti C, Alexander HR, Roberts DD, Libutti SK.

Cytokine. 2005 Jun 21;30(6):347-58. Epub 2005 Apr 7.

PMID:
15935955
22.

Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells.

Mazzanti CM, Tandle A, Lorang D, Costouros N, Roberts D, Bevilacqua G, Libutti SK.

Genome Res. 2004 Aug;14(8):1585-93.

23.

Antiangiogenic gene therapy of cancer: recent developments.

Tandle A, Blazer DG 3rd, Libutti SK.

J Transl Med. 2004 Jun 25;2(1):22.

24.

Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin.

Keezer SM, Ivie SE, Krutzsch HC, Tandle A, Libutti SK, Roberts DD.

Cancer Res. 2003 Oct 1;63(19):6405-12.

25.

HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India.

Saranath D, Khan Z, Tandle AT, Dedhia P, Sharma B, Contractor R, Shrivastava S, Dinshaw K.

Gynecol Oncol. 2002 Aug;86(2):157-62.

PMID:
12144822
26.

Determination of p53 genotypes in oral cancer patients from India.

Tandle AT, Sanghvi V, Saranath D.

Br J Cancer. 2001 Mar 23;84(6):739-42.

27.

Infrequent loss of heterozygosity at adenomatous polyposis coli gene locus in Indian oral cancers.

Tandle A, Sanghavi V, Saranath D.

Cancer Lett. 2000 Sep 1;157(2):155-60.

PMID:
10936675
28.

Characterization of Ngef, a novel member of the Dbl family of genes expressed predominantly in the caudate nucleus.

Rodrigues NR, Theodosiou AM, Nesbit MA, Campbell L, Tandle AT, Saranath D, Davies KE.

Genomics. 2000 Apr 1;65(1):53-61.

PMID:
10777665
29.

p53 inactivation in chewing tobacco-induced oral cancers and leukoplakias from India.

Saranath D, Tandle AT, Teni TR, Dedhia PM, Borges AM, Parikh D, Sanghavi V, Mehta AR.

Oral Oncol. 1999 May;35(3):242-50.

PMID:
10621843
30.

Loss of p53 gene as a biomarker of high risk oral leukoplakias.

Saranath D, Tandle AT, Deo MG, Mehta AR, Sanghvi V.

Indian J Biochem Biophys. 1997 Jun;34(3):266-73.

PMID:
9425746
31.

Detection and cloning of potent transforming gene(s) from chewing tobacco-related human oral carcinomas.

Saranath D, Bhoite LT, Deo MG, Tandle AT, D'Costa J, Kolhapure RN, Govardhan MK, Banerjee K.

Eur J Cancer B Oral Oncol. 1994 Jul;30B(4):268-77.

PMID:
7950842

Supplemental Content

Loading ...
Support Center